Last reviewed · How we verify
Terazosine — Competitive Intelligence Brief
phase 2
Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Terazosine (Terazosine) — University of Iowa.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Terazosine TARGET | Terazosine | University of Iowa | phase 2 | Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Terazosine CI watch — RSS
- Terazosine CI watch — Atom
- Terazosine CI watch — JSON
- Terazosine alone — RSS
Cite this brief
Drug Landscape (2026). Terazosine — Competitive Intelligence Brief. https://druglandscape.com/ci/terazosine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing